Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 10, 2013. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 692,000 Ordinary Shares of 25 pence each.
- Purchase Date: December 10, 2013.
- Price Range: Highest price paid was 1,597.50 pence per share; lowest price paid was 1,582.00 pence per share.
- Treasury Holdings (Settled): 515,018,909 shares (9.59% of total issued share capital).
- Treasury Holdings (Including Unsettled): 516,022,909 shares (10.62% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,856,834,967 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 692,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.62% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (515,018,909 settled vs. 516,022,909 including unsettled).
- Confirm the denominator for voting rights calculations is 4,856,834,967 shares (excluding Treasury).
- Check the price range paid (1,582.00 to 1,597.50 pence) against market prices on December 10, 2013.
- Note that this filing does not contain operational or financial performance data for the period.